LEXINGTON, Mass. and AMSTERDAM, Jan. 08, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, ...

Wednesday announced the pricing of underwritten public offering of around 4.4 million shares at $17 per share, ...

LEXINGTON, Mass. and AMSTERDAM, Jan. 07, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, ...

LEXINGTON, Mass. and AMSTERDAM, Jan. 08, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, ...

Qure (NASDAQ:QURE – Get Free Report) shares gapped down before the market opened on Friday . The stock had previously closed at $18.05, but opened at $17.55. uniQure shares last traded at $17.73, with ...

Shares of the international gene therapy developer uniQure (NASDAQ: QURE) have been soaring. Investors are responding to positive news regarding the Food and Drug Administration (FDA) and the ...

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. TipRanks is the most comprehensive data set of sell side ...

uniQure (NASDAQ:QURE – Get Free Report)’s stock price reached a new 52-week high during trading on Tuesday .The stock traded as high as $18.18 and last traded at $18.18, with a volume of 29630 ...

uniQure (NASDAQ:QURE – Get Free Report)’s share price gapped up prior to trading on Tuesday .The stock had previously closed at $17.43, but opened at $17.88. uniQure shares last traded at $16. ...

Stifel analyst Paul Matteis raised the firm’s price target on uniQure (QURE) to $32 from $12 and keeps a Buy rating on the shares. The firm is “compelled” by the already developing efficacy ...